MedPath

Efficacy Testing of Collagen and Zhuyin Drinks

Not Applicable
Completed
Conditions
Skin Condition
Interventions
Dietary Supplement: Collagen Cubilose Drink
Dietary Supplement: Placebo drink
Registration Number
NCT04266405
Lead Sponsor
TCI Co., Ltd.
Brief Summary

To assess collagen and zhuyin drink on skin \& body condition improvement

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Healthy adults aged above 20 years old
Exclusion Criteria
  • Subject who is not willing to participate in this study.
  • Patients with diseases of the skin, heart, liver, kidney, endocrine and other organs and patients with mental illness (according to medical history).
  • Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks.
  • Vegetarian
  • Subjects who have large spots (area >3 square centimeter) or abnormal acne.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Collagen and Zhuyin DrinksCollagen Cubilose Drink-
Placebo drinkPlacebo drink-
Primary Outcome Measures
NameTimeMethod
The change of skin wrinklesChange from Baseline skin wrinkles at 4 weeks

VISIA Complexion Analysis System was utilized to measure wrinkles. Units: arbitrary units

The change of skin moistureChange from Baseline skin moisture at 4 weeks

Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

The change of skin collagen densityChange from Baseline skin collagen density at 4 weeks

DermaLab® USB - 20 MHz High Freq. Ultrasound probe was utilized to scan and analyze skin collagen density. Units:Intensity score

The change of skin brightnessChange from Baseline skin brightness at 4 weeks

Glossymeter GL 200 was utilized to measure skin brightness. Units: arbitrary units

The change of interleukin-6Change from Baseline skin brightness at 4 weeks

Venous blood was sampled to measure concentrations of interleukin-6.

The change of Matrix metalloproteinase-1Change from Baseline skin brightness at 4 weeks

Venous blood was sampled to measure concentrations of Matrix metalloproteinase-1 .

The change of metallopeptidase inhibitor 1Change from Baseline skin brightness at 4 weeks

Venous blood was sampled to measure concentrations of metallopeptidase inhibitor 1.

The change of TEWLChange from Baseline TEWL at 4 weeks

Tewameter® TM 300 was utilized to measure TEWL. Units: g/h/m2

The change of interleukin-8Change from Baseline skin brightness at 4 weeks

Venous blood was sampled to measure concentrations of interleukin-8.

The change of Tumor necrosis factorChange from Baseline skin brightness at 4 weeks

Venous blood was sampled to measure concentrations of Tumor necrosis factor.

Secondary Outcome Measures
NameTimeMethod
The change of skin poresChange from Baseline skin pores at 4 weeks

VISIA Complexion Analysis System was utilized to measure skin pores. Units: arbitrary units

The change of skin textureChange from Baseline skin texture at 4 weeks

VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

The change of skin spotsChange from Baseline skin spots at 4 weeks

VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units

The change of red areasChange from Baseline red areas at 4 weeks

VISIA Complexion Analysis System was utilized to measure red areas. Units: arbitrary units

Trial Locations

Locations (1)

Chia Nan University of Pharmacy & Science

🇨🇳

Tainan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath